FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration
The private funding rose 38% amid growing international collaborations and CDMO demand
Appointment strengthens Medanta’s pediatric super-specialty and respiratory care services in the Delhi-NCR region.
Precision medicine company advances Raman spectroscopy-based therapeutic drug monitoring platform for rapid, patient-specific dosing solutions
Acquisition of medical equipment distributor aims to strengthen European commercial operations and optimise distribution costs
The microbiology unit generated $645 million in revenue in 2025 and sits within Thermo Fisher’s Specialty Diagnostics segment
His appointment is expected to further strengthen the company’s financial governance and regional operational strategy across South Asia
Subscribe To Our Newsletter & Stay Updated
